RG-7410
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified. The drug reached phase 1 clinical trials prior to the discontinuation of its development.
It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014 and a phase 1 trial was reported to have been completed by October 2014.
See also
List of investigational antipsychotics Ralmitaront (RG-7906; RO-6889450) RG-7351 Ulotaront (SEP-363856; SEP-856)
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357690383 under CC BY-SA 4.0; modifications have been made.